The oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib is superior to standard EGFR-TKIs including gefitinib and erlotinib as a first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC), according to a recent study.

Read More

Conferences

Patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease has progressed while on crizotinib (CRZ) may experience improved response rates when treated with the investigational tyrosine kinase inhibitor brigatinib, according to results presented at the 2016 American Society of Clinical Oncology Annual Meeting (June 3-7; Chicago, IL).

Read More

The addition of plinabulin to non-small cell lung cancer (NSCLC) treatment with docetaxel may reduce the frequency of adverse events and help prevent dose reductions due to toxicity, according to an abstract at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL (June 3-7, 2016).

Read More

Including certain quality measures as a part of care for patients with non-small cell lung cancer (NSCLC) who undergo surgery can significantly improve survival, according to results presented at the American Association for Thoracic Surgery Annual Meeting (May 14-18, 2016; Baltimore, MD).

Read More

Using stereotactic body radiation therapy (SBRT) to treat patients with non-small cell lung cancer (NSCLC) may slightly increase the risk of dying from a cause other than cancer, according to research presented at European Society for Radiotherapy and Oncology (ESTRO) 35 (April 29-May 3, 2016; Turin, Italy).

Read More

News

The oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib is superior to standard EGFR-TKIs including gefitinib and erlotinib as a first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC), according to a recent study.

Read More

Ethnicity, insurance status, and other factors are associated with overall survival (OS) in patients with non-small cell lung cancer (NSCLC), according to research presented at the International Association for the Study of Lung Cancer (IASLC) 18TH Annual World Conference on Lung Cancer (October 15-18, 2017; Yokohama, Japan).

Read More

Long-term data from a recent trial suggest that continuation of treatment with first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) beyond EGFR-positive non-small cell lung cancer (NSCLC) progression does not improve overall survival (OS).

Read More

The American Society of Clinical Oncology (ASCO) has updated their guideline on systemic therapy for non-small cell lung cancer (NSCLC) for the first time since 2015.

Read More

Research in Review

A second-generation inhibitor delays anaplastic lymphoma kinase (ALK)-positive lung cancer growth for a median of 15 months longer and causes fewer adverse events than the current standard of care, according to a new study presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Few patients treated with immunotherapy for metastatic non–small cell lung cancer (NSCLC) at United States community practices receive appropriate programmed death-ligand 1 (PD-L1) expression testing, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Patients with non-small cell lung cancer (NSCLC) and synchronous brain metastasis demonstrate improved 1-year and 5-year overall survival (OS) after thoracic surgery and systemic chemotherapy, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Patients with advanced non-small cell lung cancer (NSCLC) who receive previous radiotherapy are more likely to benefit from immunotherapy than those patients without previous radiotherapy, according to research published in The Lancet (published online May 24, 2017; doi:10.1016/S1470-2045(17)30380-7).

-----

Related Content

Read More

Subscribe to Non-Small Cell Lung Cancer